FLGT
Fulgent Genetics, Inc. NASDAQ Listed Sep 29, 2016$15.12
Mkt Cap $449.6M
52w Low $13.46
9.4% of range
52w High $31.04
50d MA $15.77
200d MA $22.14
P/E (TTM)
-7.2x
EV/EBITDA
-16.6x
P/B
0.4x
Debt/Equity
0.0x
ROE
-5.4%
P/FCF
-6.5x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$15.77
200d MA
$22.14
Avg Volume
567.9K
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
4978 Santa Anita Avenue · El Monte, CA 91780 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | BMO | -0.35 | -0.36 | -3.4% | 15.19 | -7.6% | -7.0% | +7.0% | -1.5% | +0.1% | +1.3% | — |
| Feb 27, 2026 | BMO | 0.03 | 0.16 | +433.3% | 24.76 | -23.2% | -38.1% | -7.4% | -2.9% | +1.5% | +1.9% | — |
| Nov 7, 2025 | BMO | -0.24 | 0.14 | +158.3% | 22.31 | +7.8% | +18.2% | +3.0% | +4.5% | +2.5% | +1.8% | — |
| Aug 1, 2025 | BMO | -0.23 | 0.07 | +130.4% | 17.18 | +12.0% | +7.9% | -0.9% | +13.2% | -0.5% | -1.3% | — |
| May 2, 2025 | BMO | -0.19 | 0.04 | +121.1% | 17.25 | +5.5% | +19.1% | -4.8% | -3.8% | -0.9% | -0.5% | — |
| Feb 28, 2025 | BMO | -0.31 | 0.04 | +112.9% | 15.69 | +1.7% | -1.5% | -1.1% | +1.6% | +7.3% | +7.5% | — |
| Nov 8, 2024 | BMO | -0.19 | 0.31 | +263.2% | 22.02 | -0.8% | -11.8% | +3.1% | -4.4% | -3.9% | -3.4% | — |
| Aug 2, 2024 | BMO | -0.31 | 0.15 | +148.4% | 23.57 | -5.4% | +6.3% | -5.5% | +2.6% | -3.2% | +4.4% | — |
| May 3, 2024 | BMO | -0.33 | -0.01 | +97.0% | 21.24 | -3.5% | +1.2% | -0.0% | -0.8% | -0.2% | +2.4% | — |
| Feb 28, 2024 | BMO | -0.30 | 0.28 | +193.3% | 25.48 | +0.0% | -8.1% | -3.6% | +3.0% | +2.2% | -2.2% | — |
| Nov 3, 2023 | BMO | -0.33 | -0.39 | -18.2% | 23.79 | +2.4% | +13.2% | +0.7% | -2.3% | -0.2% | -1.3% | — |
| Aug 4, 2023 | BMO | -0.33 | -0.08 | +75.8% | 40.08 | +9.8% | -3.0% | -12.8% | -1.6% | -1.6% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.16 | $27.47 | +1.1% | +4.5% | +2.5% | +1.8% | -1.7% | -1.0% |
| Aug 5 | UBS | Upgrade | Neutral → Buy | — | $18.36 | $19.55 | +6.5% | +13.2% | -0.5% | -1.3% | -0.2% | +1.2% |
| Aug 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.53 | $18.56 | +0.2% | -0.9% | +13.2% | -0.5% | -1.3% | -0.2% |
| May 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $19.56 | $19.65 | +0.5% | -3.8% | -0.9% | -0.5% | +6.1% | +2.1% |
| May 5 | Raymond James | Maintains | Outperform → Outperform | — | $20.54 | $19.86 | -3.3% | -4.8% | -3.8% | -0.9% | -0.5% | +6.1% |
| Mar 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.28 | $15.07 | -1.4% | +1.6% | +7.3% | +7.5% | +3.9% | -9.2% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $19.43 | $19.84 | +2.1% | +3.1% | -4.4% | -3.9% | -3.4% | -2.7% |
| Mar 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $23.22 | $23.22 | +0.0% | +0.6% | +1.2% | -3.0% | +1.5% | -2.1% |
| Oct 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $24.90 | $24.89 | -0.0% | +0.9% | -0.3% | +0.5% | +1.0% | -0.2% |
| Mar 2 | Credit Suisse | Maintains | Outperform → Outperform | — | $31.85 | $31.39 | -1.4% | +4.9% | +1.0% | -7.5% | -0.1% | +0.8% |
| Dec 8 | Piper Sandler | Downgrade | Overweight → Neutral | — | $37.07 | $35.67 | -3.8% | -9.1% | +1.1% | -2.1% | +1.0% | +0.0% |
| Nov 18 | Raymond James | Maintains | Outperform → Outperform | — | $35.89 | $37.24 | +3.8% | +3.2% | -0.9% | -2.0% | +1.4% | +1.1% |
| Nov 14 | Credit Suisse | Maintains | Outperform → Outperform | — | $39.24 | $38.73 | -1.3% | -8.5% | +3.1% | -2.9% | -0.2% | +3.2% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.24 | $38.73 | -1.3% | -8.5% | +3.1% | -2.9% | -0.2% | +3.2% |
| Aug 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $46.96 | $47.77 | +1.7% | +2.4% | -3.6% | -3.5% | -1.4% | -1.5% |
| May 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $54.45 | $54.31 | -0.3% | -1.5% | +5.7% | -2.2% | +3.8% | -2.7% |
| Jan 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $60.72 | $60.10 | -1.0% | +4.6% | -2.4% | -2.4% | +3.5% | +2.0% |
| Aug 10 | Credit Suisse | Maintains | Underperform → Underperform | — | $109.76 | $95.00 | -13.4% | -11.3% | -2.2% | +4.2% | -4.9% | +1.9% |
| Mar 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $85.53 | $110.88 | +29.6% | +8.0% | +2.4% | +15.9% | -11.3% | +5.2% |
| Feb 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $110.49 | $112.30 | +1.6% | +24.8% | -18.2% | +12.3% | -5.9% | +18.7% |
| Jan 8 | Credit Suisse | Downgrade | Neutral → Underperform | — | $70.84 | $71.00 | +0.2% | -10.6% | -2.0% | +12.6% | -0.1% | -1.1% |
| Nov 24 | BTIG | Downgrade | Buy → Neutral | — | $43.60 | $42.35 | -2.9% | -15.3% | -1.2% | +11.3% | +10.6% | +2.1% |
| Sep 25 | Credit Suisse | Maintains | Neutral → Neutral | — | $39.52 | $39.53 | +0.0% | -0.4% | -1.1% | +7.4% | -4.2% | +1.4% |
| Aug 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $44.01 | $45.38 | +3.1% | +14.8% | -5.0% | -4.9% | +0.6% | -2.5% |
| Jul 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $19.51 | $19.92 | +2.1% | +35.6% | -2.9% | -0.1% | +1.8% | +0.9% |
| Jun 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.50 | $19.30 | +17.0% | -1.0% | +2.4% | +0.5% | +2.3% | +1.8% |
| May 29 | BTIG | Maintains | Buy → Buy | — | $16.06 | $16.70 | +4.0% | +8.5% | +3.3% | +1.6% | -3.7% | -4.0% |
| May 5 | Credit Suisse | Maintains | Neutral → Neutral | — | $16.48 | $16.91 | +2.6% | -23.5% | +15.5% | +7.6% | +5.7% | +1.1% |
| Nov 5 | Piper Jaffray | Upgrade | Neutral → Overweight | — | $9.40 | $11.50 | +22.3% | +38.4% | -8.3% | +3.3% | +28.4% | -6.1% |
| Nov 5 | Piper Sandler | Upgrade | Neutral → Overweight | — | $9.40 | $11.50 | +22.3% | +38.4% | -8.3% | +3.3% | +28.4% | -6.1% |
| Apr 26 | Credit Suisse | Downgrade | Outperform → Neutral | — | $7.35 | $7.25 | -1.4% | -6.8% | -3.8% | +0.9% | +3.0% | +0.7% |
| May 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.88 | $3.80 | -2.0% | -2.3% | -2.4% | +2.7% | -2.4% | +0.0% |
| Mar 1 | Piper Sandler | Downgrade | Overweight → Neutral | — | $4.79 | $4.58 | -4.4% | -10.0% | -11.4% | -1.8% | +1.3% | +0.3% |
| Mar 1 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.79 | $4.58 | -4.4% | -10.0% | -11.4% | -1.8% | +1.3% | +0.3% |
| Mar 1 | PiperJaffray | Downgrade | Overweight → Neutral | — | $4.79 | $4.58 | -4.4% | -10.0% | -11.4% | -1.8% | +1.3% | +0.3% |
| Nov 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.05 | $3.33 | -17.8% | -14.3% | -1.2% | -2.2% | -1.0% | -1.8% |
| Aug 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.14 | $5.76 | -6.2% | -12.2% | +4.6% | +2.5% | -0.3% | +2.8% |
| Oct 24 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.88 | $8.85 | -0.3% | +2.6% | +2.1% | -3.0% | -0.3% | +1.1% |
| Oct 24 | BTIG Research | Maintains | Buy → Buy | — | $8.88 | $8.85 | -0.3% | +2.6% | +2.1% | -3.0% | -0.3% | +1.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more details about the executive change to provide meaningful analysis. Could you clarify:
1. Which company (CNVS or FLGT)?
2. What position changed?
3. Is this a departure, hire, or promotion?
4. Who is involved?
Without these specifics, I cannot write an accurate assessment of stock implications.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.
Mar 30
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
FLGT completed a $43M acquisition, which could accelerate growth and market expansion, though investors should monitor integration costs and whether synergies justify the purchase price.
Mar 17
8-K · 7.01
! Medium
Fulgent Genetics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Fulgent Genetics updated its investor presentation on February 27, 2026, providing current business summaries and updates available on its investor relations website.
Feb 27
Data updated apr 25, 2026 9:20am
· Source: massive.com